FDA approves Tyruko, first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis – Sandoz
Sandoz, a global leader in generic and biosimilar medicines, announced that the FDA has approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat… read more.
